Laron-type dwarfism, I a syndrome of growth hormone (GH) receptor deficiency, is an autosomal recessive disorder caused by a variable genetic defect of the GH receptor.s-' The phenotype of the patients with Laron-type dwarfism (LTD) resembles isolated GH deficiency." LTO is characterized by extremely low serum insulin-like growth factor-I (IGF-I) despite normal or high concentrations of biologically active GH and by resistance to exogenous GH. 5 The defect in the GH receptor results in deficiencies of IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3), the major serum carrier protein of IGF peptides.s?
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Purification and protein sequencing revealed that serum growth hormone binding protein (GHBP) was structurally identical to the extracellular hormone binding domain of the membrane-bound GH receptor." The GHBP was noted to be absent in some LTO patientsv'" and normal in others. II We present here an unusual case of GH receptor defect and the members of two unconnected families, one with three siblings with LTO and GHBP-negative phenotype and the other with one child with L TO and GHBPpositive phenotype.
SUBJECTS AND METHODS

Subjects
JG (unusual GH receptor case)
JG, a boy born in 1980 at 33 weeks by Caesarean section, weighed 1·30 kg at birth. He suffered intra-uterine growth retardation and his birth height was 7-8 standard deviation (SO) below the mean height for age. At age 15, his height was 115 em (9 SO below the mean height for age). Random serum concentrations of GH and IFG-I were 19 mUll and 0·05 U/mL, respectively. In response to clonidine administration Correspondence to: P Y P Kwong.
an exaggerated GH response, peaking at 188 m U/L was seen. His parents were white Caucasians, were related and were both small, neither of them taller than 165 cm. There was one other sibling in the family, who was of normal stature.
Family H (GHBP-negative)
In this family a 3-year-old girl was the only affected member. Two siblings and both parents were of normal stature. There was consanguinity in the family and the parents were of Kuwaiti origin. The affected girl's height was 70·5 em (6 SO below the mean height for age) and she showed typical features of Laron-type dwarfism. A peak serum GH of 270mU/L occurred during multiple sampling over 24 h and very low GHBP activity was observed.
Family K (GHBP-positive)
Three siblings from this family of five children showed the phenotype of LTO. The affected children (aged I~, IS and 16 years) were very short being between 4 to 5 SO below the mean height for age. All had raised serum concentrations of GH, low serum IGF-I concentrations and positive GHBP activity. The parents were unrelated and were of Northern Indian origin. Both parents and unaffected siblings were of normal stature. The clinical and biochemical characteristics of the family have been described earlier.
Clinical Investigations JG underwent a 4-day treatment with GH (0,1 units/kg subcutaneous injections). Blood samples were collected before and after the treatment for the measurement of serum IGF-I, IGF-II and IGFBP-3.
Samples were collected, following an overnight fast, from the children of the two families studied and were assayed for serum IGF-I, IGF-II and IGFBP-3.
Methods
IGF-I and IGF-ll
Serum IGF-I and IGF-II were measured by competitive, double antibody radioimmunoassay after acid-ethanol extraction.P The betweenassay imprecision for IGF-I was 17·9% at 0·16 U jmL, 10·0% at 0·40 U jmL, 8·6% at 0·65 U jmL and 9·0% at 1·38 U jmL. The between-assay imprecision for IGF-II was 15·6% at 0'36UjmL, 10·1% at 0'59UjmL, 8·0% at 0·80 UjmL and 7·7% at 0·88 UjmL.
IGFBP-3
The radioimmunoassay for the measurement of IGFBP-3 was based on that described by Baxter and Martin." Biosynthetic IGF-I was iodinated using a modified method to that of Baxter and Brown.'? The assay tracer was produced by the covalent interaction of 125I-IGF_I with biosynthe tic glycosylated IGFBP-3. A normal adult human serum pool was used as a standard reference preparation. This pool was calibrated against standard dilution of the original stock glycosylated IGFBP-3 preparation. Tracer and standard were incubated with a rabbit polyclonal antiserum raised against biosynthetic nonglycosylated IGFBP-3. Sac-Cel donkey anti-rabbit antibody coated cellulose suspension (lOS Ltd, Boldon, UK) was used as the separation reagent.
Between-assay imprecision was 18·4% at 2·0 mgj L, 13·9% at 2'9mg/L and 11-4% at 3-4mg/L. The detection limit (3S0 at zero dose) was 0·2 mg/L,
RESULTS
The serum IGF-I, IGF-II and IGFBP-3 concentrations of the children of the two families are shown in Table I . The LTO patients, both GHBP-negative and GHBP-positive, had very low biochemical markers compared with the unaffected members of the family. The unaffected sister (Child I in Family K), aged II who was entering puberty, had the highest concentrations of all three parameters.
The IGF-I concentrations in JG was very low and was unchanged by the GH therapy (Table I) . The IGF-II and IGFBP-3 concentrations were either normal or at the upper limit of normal for the assays.
DISCUSSION
The LTO children of the two families (Family H, GHBP-negative; Family K, GHBP-positive) all had low serum IGF-I and IGF-II concentrations despite high serum GH concentrations. Serum IGFBP-3 concentrations in the LTO patients were all below the reference range for age as previously reported.i-"
In contrast, JG had IGFBP-3 and IGF-II concentrations either normal or above normal despite extremely low IGF-I concentrations. The very low IGF-I concentration found in JG in combination with an exaggerated GH response to clonidine stimulation and an inability to generate IGF-I in response to exogeneous GH are consistent with the diagnosis of LTO. The IGF-I synthetic pathway is affected in JG as in the LTO patients in the two families. The atypical findings in JG are the high-normal basal concentrations of IGF-II and IGFBP-3 which appeared to rise with exogenous GH. This would suggest that the defect in JG differs from the LTD children in that only the signal transmission required for the synthesis of IGF-I is affected in the former whereas both the IGF-I synthetic and generation pathways for IGF-II and IGFBP-3 are defective in the latter. Laron et al.'! described three LTD patients with pathology affecting only IGF-I generation and sparing the IGFBP-3 synthetic pathway. These patients were found to have normal basal serum GHBP and IGFBP-3 concentrations (the latter determined by Western ligand and immunoblotting). After 7 days of GH administration serum IGFBP-3 concentrations increased.
We have described an unusual case of LTD, possibly a variant with defective IGF-I but normal IGF-II and IGFBP-3 synthetic pathways. Studies to characterize the serum GHBP and the GH receptor gene will help to define this variant defect and to improve our current knowledge of post-GH receptor regulatory mechanisms.
